SK Pharmteco, a subsidiary of SK Inc., is consolidating its global pharmaceutical manufacturing operations under a single brand, bringing together six separate facilities that span drug development, manufacturing, and testing services. The unified organization includes SK biotek operations in South Korea and Ireland, U.S.-based AMPAC units, and European cell therapy specialist Yposkesi.
The reorganization aims to create a more integrated service offering for pharmaceutical clients, from early-stage drug development through commercial production. CEO Joerg Ahlgrimm said the move would help deliver therapies to patients more efficiently.
The rebranding includes a new website and updated visual identity across all locations. While individual facilities will maintain their operations, they will now operate under the SK pharmteco name.
The company maintains facilities across North America, Europe and Asia. Its services span small molecule drug ingredients, cell and gene therapy manufacturing, and analytical testing. The consolidation reflects growing competition in the contract manufacturing sector as drug companies increasingly outsource production.
This reorganization follows SK Pharmteco’s recent expansion in the weight-loss drug market through a major manufacturing contract worth up to 2 trillion won ($1.4 billion).
